Addex Therapeutics Aktie
| 0,06CHF | 0,00CHF | -0,31% | 
WKN DE: A0MSH6 / ISIN: CH0029850754
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 27 | 28 | 24 | 23 | 2 | 
| Umsatz pro Mitarbeiter in Mio. EUR | 0,13 | 0,10 | 0,06 | 0,07 | 0,21 | 
Bilanz (in Mio. CHF) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 19 | 22 | 8 | 4 | 4 | 
| Summe Anlagevermögen | 1 | 1 | 0 | 0 | 7 | 
| Summe Aktiva | 20 | 23 | 8 | 5 | 11 | 
Bilanz (in Mio. CHF) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 6 | 6 | 3 | 3 | 1 | 
| Summe Eigenkapital | 15 | 17 | 5 | 1 | 10 | 
| Summe Passiva | 20 | 23 | 8 | 5 | 11 | 
Adresse
| 9, Chemin des Mines, 1202 Geneva | |
| Telefon | +41 (22) 884-15-55 | 
| Fax | +41 (22) 884-15-56 | 
| Internet | http://www.addextherapeutics.com | 
Management
| Isaac Manke Independent Non-Executive Director | 
| Jake R. Nunn Independent Non-Executive Director | 
| Lénaic Teyssédou Executive Manager & Head-Group Finance | 
| Raymond George Hill Non-Executive Director | 
| Roger G. Mills Non-Executive Director & Chief Medical Officer | 
| Timothy Dyer Chief Executive Officer & Executive Director | 
| Vincent M. Lawton Chairman | 
 
									 
									 
								